Safety, Tolerability and Preliminary Efficacy of 161Tb-LNC1011 (PSMA Radioligand) in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

by | Feb 2, 2026 | Clinical Trials | 0 comments

​ Conditions: Prostate Cancer

Interventions: Drug: 161Tb-LNC1011

Sponsors: Peking Union Medical College Hospital; Mianyang Central Hospital

Not yet recruiting Conditions: Prostate Cancer
Interventions: Drug: 161Tb-LNC1011
Sponsors: Peking Union Medical College Hospital; Mianyang Central Hospital
Not yet recruiting 

Submit a Comment

Your email address will not be published. Required fields are marked *